ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced today that it has been awarded grants totaling $822,137 through the US Federal Government’s Qualifying Therapeutic Discovery Project.